An Open,Multicentre,Prospective Study of Adjuvant Zoledronate Treatment in Osteoporosis Women With Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Breast cancer; Osteoporosis
- Focus Therapeutic Use
- Acronyms BLAZE
- 17 Oct 2012 Planned end date changed from 1 Jun 2014 to 1 Jun 2017 as reported by ClinicalTrials.gov.
- 26 Jun 2012 New trial record
- 25 Jun 2012 Additional lead trial investigator (Shenming Wang) identified as reported by ClinicalTrials.gov.